首页> 美国卫生研究院文献>other >Massively Parallel DNA Sequencing Successfully Identifies New Causative Mutations in Deafness Genes in Patients with Cochlear Implantation and EAS
【2h】

Massively Parallel DNA Sequencing Successfully Identifies New Causative Mutations in Deafness Genes in Patients with Cochlear Implantation and EAS

机译:大规模平行DNA测序成功地确定了人工耳蜗植入和EAS患者耳聋基因的新致突变。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Genetic factors, the most common etiology in severe to profound hearing loss, are one of the key determinants of Cochlear Implantation (CI) and Electric Acoustic Stimulation (EAS) outcomes. Satisfactory auditory performance after receiving a CI/EAS in patients with certain deafness gene mutations indicates that genetic testing would be helpful in predicting CI/EAS outcomes and deciding treatment choices. However, because of the extreme genetic heterogeneity of deafness, clinical application of genetic information still entails difficulties. Target exon sequencing using massively parallel DNA sequencing is a new powerful strategy to discover rare causative genes in Mendelian disorders such as deafness. We used massive sequencing of the exons of 58 target candidate genes to analyze 8 (4 early-onset, 4 late-onset) Japanese CI/EAS patients, who did not have mutations in commonly found genes including GJB2, SLC26A4, or mitochondrial 1555A>G or 3243A>G mutations. We successfully identified four rare causative mutations in the MYO15A, TECTA, TMPRSS3, and ACTG1 genes in four patients who showed relatively good auditory performance with CI including EAS, suggesting that genetic testing may be able to predict the performance after implantation.
机译:遗传因素是重度至重度听力丧失的最常见病因,是决定人工耳蜗植入(CI)和电声刺激(EAS)结果的关键因素之一。患有某些耳聋基因突变的患者接受CI / EAS后的令人满意的听觉表现表明,基因检测将有助于预测CI / EAS的结果并决定治疗的选择。然而,由于耳聋的极端遗传异质性,遗传信息的临床应用仍然存在困难。使用大规模平行DNA测序的靶标外显子测序是一种新的强大策略,可发现孟德尔疾病(如耳聋)中罕见的致病基因。我们对58个靶候选基因的外显子进行了大规模测序,以分析8名(4例早发,4例晚发)日本CI / EAS患者,这些患者在常见基因(包括GJB2,SLC26A4或线粒体1555A)中均未发生突变。 G或3243A> G突变。我们成功地在包括EAS在内的CI表现出相对良好的听觉表现的四名患者中成功鉴定出MYO15A,TECTA,TMPRSS3和ACTG1基因中的四个罕见致病突变,这表明基因测试可能能够预测植入后的表现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号